Peptidomics‑Based Antigen Discovery and Prediction
Across immunotherapy, vaccine development, and infectious disease preparedness, the ability to pinpoint truly effective antigens represents the starting point for downstream strategy design. Genome sequencing coupled with bioinformatics prediction can rapidly generate lists of putative antigenic targets; however, two practical limitations are frequently encountered: (i) predicted candidates are not necessarily processed and presented to T cells under physiological conditions; and (ii) systematic biases among algorithms and reference databases can yield a high false-positive rate, thereby increasing the burden and cost of experimental validation. Against this backdrop, peptidomics offers a solution that is more tightly aligned with biological reality. By leveraging high-resolution mass spectrometry to directly characterize peptides bound to the major histocompatibility complex (MHC), peptidomics reveals the molecular fragments that are actually displayed by the immune system in a given disease context. Consequently, investigators can directly capture peptides that truly participate in immune responses from an otherwise vast protein milieu, markedly improving the accuracy and efficiency of neoantigen discovery. Today, from tumor neoantigen vaccine development to the surveillance and control of emerging viral variants, peptidomics is increasingly viewed as a “treasure map” for immunological research. Through mass spectrometry-based, direct characterization of MHC-bound peptides, it discloses molecular information that the immune system truly presents to T cells, thereby moving antigen discovery from theoretical inference toward experimental verification.
Technical Principles and Experimental Workflow of Peptidomics
Peptidomics is a major branch of proteomics focused on naturally occurring short peptides in vivo. Its central objective is to identify and quantify these endogenous peptides in complex biological matrices, with particular emphasis on immune-relevant peptides that bind to MHC molecules. A typical experimental workflow includes:
1. Immunoaffinity Purification (Immunoaffinity Purification)
MHC-I or MHC-II complexes are enriched from the cell surface using highly specific antibodies, thereby co-purifying the MHC molecules together with their associated peptides. This step critically depends on antibody specificity and appropriately gentle elution conditions to preserve peptide integrity and maintain the native structural features of the bound peptides.
2. Peptide Release and Separation
MHC-associated peptides are released using acidic dissociation or organic solvent-based approaches, followed by high-performance liquid chromatography (LC) separation to reduce matrix complexity and minimize background interference.
3. High-Resolution Mass Spectrometry Detection (LC-MS/MS)
Tandem mass spectrometry is performed on high-resolution platforms (e.g., Orbitrap and Q-TOF instruments) to determine accurate peptide masses and fragmentation patterns, enabling amino-acid sequence assignment.
4. Data Interpretation and Antigen Prediction
Identified peptides are mapped to their source proteins through database searching, and immunoinformatics tools (e.g., NetMHCpan and MHCflurry) are further applied to predict MHC-binding capacity and immunogenic potential.
Core Advantages of Peptidomics in Antigen Discovery
1. From Prediction to Validation
(1) Prediction: HLA-binding peptides are inferred primarily through algorithms and are therefore susceptible to reference-database limitations and model-dependent biases.
(2) Peptidomics validation: naturally occurring MHC-bound peptides are captured directly, providing an experimental readout that reflects the true state of immune presentation.
2. High Physiological Relevance
Peptidomics yields peptide sequences that are genuinely presented on the cell surface, thereby enabling the exclusion of false-positive targets that may be expressed in vitro yet fail to be processed and loaded onto MHC molecules.
3. Applicability to Multiple Scenarios
(1) Tumor immunity: tumor-specific mutant peptides can be discovered to support personalized neoantigen vaccine design.
(2) Infectious disease prevention and control: pathogen-related peptides presented by MHC following viral infection can be characterized to inform and accelerate vaccine development.
(3) Autoimmune mechanism research: aberrantly presented self-peptides can be identified to facilitate mechanistic investigations into disease onset and progression.
Computational Support for Antigen Prediction
Even when large numbers of immunopeptides have been experimentally measured, predictive modeling remains essential, particularly for prioritizing high-potential antigen candidates.
1. Binding affinity prediction: deep learning-based models are used to estimate the binding strength between peptides and MHC molecules.
2. Immunogenicity assessment: the likelihood that peptide-MHC complexes will activate T cells is predicted to support candidate ranking.
3. Multi-omics integration: transcriptomic and proteomic evidence is integrated to filter out background peptides that are lowly expressed or not translated.
Challenges From Laboratory to Clinical Translation
1. Difficulty in Detecting Low-Abundance Peptides
This application places stringent demands on mass spectrometric sensitivity, suppression of background noise, and the robustness of sample preparation and handling procedures.
2. HLA Diversity
Given substantial inter-individual variation in HLA alleles, diverse and well-curated reference resources are required, including the construction of broadly representative databases.
3. Complex Data Interpretation
Antigen presentation is shaped by multiple determinants, including protein degradation pathways, peptide loading mechanisms, and cell-type-specific biology, which collectively complicate interpretation.
Peptidomics-based antigen discovery and prediction is bringing unprecedented precision and efficiency to immunotherapy and vaccine development. It not only compresses the timeline from target discovery to validation, but also enables strategy design grounded in authentic immune-presentation evidence. MtoZ Biolabs is committed to advancing innovation and translational application of peptidomics, supporting scientists worldwide in rapidly identifying actionable immune targets and progressing toward the future of precision medicine.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
